PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC)

被引：0
|
作者：
Tannir, Nizar M.
Agarwal, Neeraj
Pal, Sumanta K.
Cho, Daniel C.
Formiga, Maria
Guo, Jun
George, Daniel J.
Tagliaferri, Mary Ann
Singel, Stina Mui
O'Keeffe, Bridget A.
Hannah, Alison L.
Balbas, Minna
Penkov, Konstantin
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] NYU, Perlmutter Canc Ctr, Langone Hlth, New York, NY USA
[5] AC Camargo Canc Ctr, Sao Paulo, Brazil
[6] Peking Univ, Canc Hosp & Inst, Beijing Shi, Peoples R China
[7] Duke Univ, Sch Med, Durham, NC USA
[8] Nektar Therapeut, San Francisco, CA USA
[9] Private Med Inst Euromedserv, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS763
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nivolumab combined with Ipilimumab versus Sunitinib-Monotherapy-SUNNIFORECAST - AN 41/16 of the AUO Phase-II randomized, open-label Study in Patients with previously untreated and advanced (unresectable or metastatic) non-clear cell Renal Cell Carcinoma
    Rexer, H.
    Steiner, T.
    Bergmann, L.
    UROLOGE, 2017, 56 (06): : 802 - 803
  • [22] Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
    Larkin, James
    Minor, David
    D'Angelo, Sandra
    Neyns, Bart
    Smylie, Michael
    Miller, Wilson H., Jr.
    Gutzmer, Ralf
    Linette, Gerald
    Chmielowski, Bartosz
    Lao, Christopher D.
    Lorigan, Paul
    Grossmann, Kenneth
    Hassel, Jessica C.
    Sznol, Mario
    Daud, Adil
    Sosman, Jeffrey
    Khushalani, Nikhil
    Schadendorf, Dirk
    Hoeller, Christoph
    Walker, Dana
    Kong, George
    Horak, Christine
    Weber, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 383 - +
  • [23] A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO
    Rexer, H.
    Bergmann, L.
    Steiner, T.
    AKTUELLE UROLOGIE, 2020, 51 (03) : 236 - 238
  • [24] TEMPORAL TRENDS IN GRADE 3/4 ADVERSE EVENTS AND ASSOCIATED COSTS OF NIVOLUMAB PLUS CABOZANTINIB (N plus C) VERSUS SUNITINIB (S) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC)
    Geynisman, D.
    McGregor, B.
    Burotto, M.
    Porta, C.
    Suarez, C.
    Bourlon, M. T.
    Stwalley, B.
    Du, E. X.
    Gu, C.
    Yang, X.
    Betts, K. A.
    Huo, S.
    Choueiri, T. K.
    VALUE IN HEALTH, 2021, 24 : S36 - S36
  • [25] Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
    Satoshi Tamada
    Chihiro Kondoh
    Nobuaki Matsubara
    Ryuichi Mizuno
    Go Kimura
    Satoshi Anai
    Yoshihiko Tomita
    Masafumi Oyama
    Naoya Masumori
    Takahiro Kojima
    Hiroaki Matsumoto
    Mei Chen
    Mengran Li
    Kenji Matsuda
    Yoshinobu Tanaka
    Brian I. Rini
    Hirotsugu Uemura
    International Journal of Clinical Oncology, 2022, 27 : 154 - 164
  • [26] Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
    Rini, Brian I.
    Powles, Thomas
    Atkins, Michael B.
    Escudier, Bernard
    McDermott, David F.
    Suarez, Cristina
    Bracarda, Sergio
    Stadler, Walter M.
    Donskov, Frede
    Lee, Jae Lyun
    Hawkins, Robert
    Ravaud, Alain
    Alekseev, Boris
    Staehler, Michael
    Uemura, Motohide
    De Giorgi, Ugo
    Mellado, Begona
    Porta, Camillo
    Melichar, Bohuslav
    Gurney, Howard
    Bedke, Jens
    Choueiri, Toni K.
    Parnis, Francis
    Khaznadar, Tarik
    Thobhani, Alpa
    Li, Shi
    Piault-Louis, Elisabeth
    Frantz, Gretchen
    Huseni, Mahrukh
    Schiff, Christina
    Green, Marjorie C.
    Motzer, Robert J.
    LANCET, 2019, 393 (10189) : 2404 - 2415
  • [27] Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
    Tamada, Satoshi
    Kondoh, Chihiro
    Matsubara, Nobuaki
    Mizuno, Ryuichi
    Kimura, Go
    Anai, Satoshi
    Tomita, Yoshihiko
    Oyama, Masafumi
    Masumori, Naoya
    Kojima, Takahiro
    Matsumoto, Hiroaki
    Chen, Mei
    Li, Mengran
    Matsuda, Kenji
    Tanaka, Yoshinobu
    Rini, Brian, I
    Uemura, Hirotsugu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 154 - 164
  • [28] A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
    John D. Hainsworth
    James A. Reeves
    Joseph R. Mace
    Edward J. Crane
    Oday Hamid
    John R. Stille
    Amy Flynt
    Stephanie Roberson
    John Polzer
    Edward R. Arrowsmith
    Targeted Oncology, 2016, 11 : 643 - 653
  • [29] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Apolo, Andrea B.
    Choueiri, Toni K.
    LANCET ONCOLOGY, 2022, 23 (02) : 292 - 303
  • [30] A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
    Hainsworth, John D.
    Reeves, James A.
    Mace, Joseph R.
    Crane, Edward J.
    Hamid, Oday
    Stille, John R.
    Flynt, Amy
    Roberson, Stephanie
    Polzer, John
    Arrowsmith, Edward R.
    TARGETED ONCOLOGY, 2016, 11 (05) : 643 - 653
12345